Benzothiophene carboxylate derivatives as novel allosteric inhibitors of branched-chain α-ketoacid dehydrogenase kinase

Shih Chia Tso, Wen Jun Gui, Cheng Yang Wu, Jacinta L. Chuang, Xiangbing Qi, Kristen J. Skvorak, Kenneth Dorko, Amy L. Wallace, Lorraine K. Morlock, Brendan H. Lee, Susan M. Hutson, Stephen C. Strom, Noelle S. Williams, Uttam K. Tambar, R. Max Wynn, David T. Chuang

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The mitochondrial branched-chain α-ketoacid dehydrogenase complex (BCKDC) is negatively regulated by reversible phosphorylation.BCKDCkinase (BDK) inhibitors that augment BCKDC flux have been shown to reduce branched-chain amino acid (BCAA) concentrations in vivo. In the present study, we employed high-throughput screens to identify compound 3,6-dichlorobenzo[b]thiophene-2- carboxylic acid (BT2) as a novel BDK inhibitor (IC50 = 3.19 μM). BT2 binds to the same site in BDK as other known allosteric BDK inhibitors, including (S)-α-cholorophenylproprionate ((S)-CPP). BT2 binding to BDK triggers helix movements in the N-terminal domain, resulting in the dissociation of BDK from the BCKDC accompanied by accelerated degradation of the released kinase in vivo. BT2 shows excellent pharmacokinetics (terminal T1/2 = 730 min) and metabolic stability (no degradation in 240 min), which are significantly better than those of (S)-CPP. BT2, its analog 3-chloro-6- fluorobenzo[b]thiophene-2-carboxylic acid (BT2F), and a prodrug of BT2 (i.e. N-(4-acetamido-1,2,5-oxadiazol-3-yl)-3,6-dichlorobenzo[b]thiophene-2- carboxamide (BT3)) significantly increase residualBCKDCactivity in cultured cells and primary hepatocytes from patients and a mouse model of maple syrup urine disease. Administration of BT2 at 20 mg/kg/day to wild-type mice for 1 week leads to nearly complete dephosphorylation and maximal activation of BCKDC in heart, muscle, kidneys, and liver with reduction in plasmaBCAAconcentrations. The availability of benzothiophene carboxylate derivatives as stable BDK inhibitors may prove useful for the treatment of metabolic disease caused by elevated BCAA concentrations.

Original languageEnglish (US)
Pages (from-to)20583-20593
Number of pages11
JournalJournal of Biological Chemistry
Volume289
Issue number30
DOIs
StatePublished - Jul 25 2014

Fingerprint

3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide)
Phosphotransferases
Derivatives
Branched Chain Amino Acids
Maple Syrup Urine Disease
Degradation
Thiophenes
Phosphorylation
Pharmacokinetics
thiophene-2-carboxylate
benzothiophene
Metabolic Diseases
Prodrugs
Liver
Inhibitory Concentration 50
Muscle
Hepatocytes
Cultured Cells
Myocardium
Chemical activation

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology
  • Medicine(all)

Cite this

Benzothiophene carboxylate derivatives as novel allosteric inhibitors of branched-chain α-ketoacid dehydrogenase kinase. / Tso, Shih Chia; Gui, Wen Jun; Wu, Cheng Yang; Chuang, Jacinta L.; Qi, Xiangbing; Skvorak, Kristen J.; Dorko, Kenneth; Wallace, Amy L.; Morlock, Lorraine K.; Lee, Brendan H.; Hutson, Susan M.; Strom, Stephen C.; Williams, Noelle S.; Tambar, Uttam K.; Wynn, R. Max; Chuang, David T.

In: Journal of Biological Chemistry, Vol. 289, No. 30, 25.07.2014, p. 20583-20593.

Research output: Contribution to journalArticle

Tso, SC, Gui, WJ, Wu, CY, Chuang, JL, Qi, X, Skvorak, KJ, Dorko, K, Wallace, AL, Morlock, LK, Lee, BH, Hutson, SM, Strom, SC, Williams, NS, Tambar, UK, Wynn, RM & Chuang, DT 2014, 'Benzothiophene carboxylate derivatives as novel allosteric inhibitors of branched-chain α-ketoacid dehydrogenase kinase', Journal of Biological Chemistry, vol. 289, no. 30, pp. 20583-20593. https://doi.org/10.1074/jbc.M114.569251
Tso, Shih Chia ; Gui, Wen Jun ; Wu, Cheng Yang ; Chuang, Jacinta L. ; Qi, Xiangbing ; Skvorak, Kristen J. ; Dorko, Kenneth ; Wallace, Amy L. ; Morlock, Lorraine K. ; Lee, Brendan H. ; Hutson, Susan M. ; Strom, Stephen C. ; Williams, Noelle S. ; Tambar, Uttam K. ; Wynn, R. Max ; Chuang, David T. / Benzothiophene carboxylate derivatives as novel allosteric inhibitors of branched-chain α-ketoacid dehydrogenase kinase. In: Journal of Biological Chemistry. 2014 ; Vol. 289, No. 30. pp. 20583-20593.
@article{1bca476aaa1e4b00a12d325b8dacd9a2,
title = "Benzothiophene carboxylate derivatives as novel allosteric inhibitors of branched-chain α-ketoacid dehydrogenase kinase",
abstract = "The mitochondrial branched-chain α-ketoacid dehydrogenase complex (BCKDC) is negatively regulated by reversible phosphorylation.BCKDCkinase (BDK) inhibitors that augment BCKDC flux have been shown to reduce branched-chain amino acid (BCAA) concentrations in vivo. In the present study, we employed high-throughput screens to identify compound 3,6-dichlorobenzo[b]thiophene-2- carboxylic acid (BT2) as a novel BDK inhibitor (IC50 = 3.19 μM). BT2 binds to the same site in BDK as other known allosteric BDK inhibitors, including (S)-α-cholorophenylproprionate ((S)-CPP). BT2 binding to BDK triggers helix movements in the N-terminal domain, resulting in the dissociation of BDK from the BCKDC accompanied by accelerated degradation of the released kinase in vivo. BT2 shows excellent pharmacokinetics (terminal T1/2 = 730 min) and metabolic stability (no degradation in 240 min), which are significantly better than those of (S)-CPP. BT2, its analog 3-chloro-6- fluorobenzo[b]thiophene-2-carboxylic acid (BT2F), and a prodrug of BT2 (i.e. N-(4-acetamido-1,2,5-oxadiazol-3-yl)-3,6-dichlorobenzo[b]thiophene-2- carboxamide (BT3)) significantly increase residualBCKDCactivity in cultured cells and primary hepatocytes from patients and a mouse model of maple syrup urine disease. Administration of BT2 at 20 mg/kg/day to wild-type mice for 1 week leads to nearly complete dephosphorylation and maximal activation of BCKDC in heart, muscle, kidneys, and liver with reduction in plasmaBCAAconcentrations. The availability of benzothiophene carboxylate derivatives as stable BDK inhibitors may prove useful for the treatment of metabolic disease caused by elevated BCAA concentrations.",
author = "Tso, {Shih Chia} and Gui, {Wen Jun} and Wu, {Cheng Yang} and Chuang, {Jacinta L.} and Xiangbing Qi and Skvorak, {Kristen J.} and Kenneth Dorko and Wallace, {Amy L.} and Morlock, {Lorraine K.} and Lee, {Brendan H.} and Hutson, {Susan M.} and Strom, {Stephen C.} and Williams, {Noelle S.} and Tambar, {Uttam K.} and Wynn, {R. Max} and Chuang, {David T.}",
year = "2014",
month = "7",
day = "25",
doi = "10.1074/jbc.M114.569251",
language = "English (US)",
volume = "289",
pages = "20583--20593",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "30",

}

TY - JOUR

T1 - Benzothiophene carboxylate derivatives as novel allosteric inhibitors of branched-chain α-ketoacid dehydrogenase kinase

AU - Tso, Shih Chia

AU - Gui, Wen Jun

AU - Wu, Cheng Yang

AU - Chuang, Jacinta L.

AU - Qi, Xiangbing

AU - Skvorak, Kristen J.

AU - Dorko, Kenneth

AU - Wallace, Amy L.

AU - Morlock, Lorraine K.

AU - Lee, Brendan H.

AU - Hutson, Susan M.

AU - Strom, Stephen C.

AU - Williams, Noelle S.

AU - Tambar, Uttam K.

AU - Wynn, R. Max

AU - Chuang, David T.

PY - 2014/7/25

Y1 - 2014/7/25

N2 - The mitochondrial branched-chain α-ketoacid dehydrogenase complex (BCKDC) is negatively regulated by reversible phosphorylation.BCKDCkinase (BDK) inhibitors that augment BCKDC flux have been shown to reduce branched-chain amino acid (BCAA) concentrations in vivo. In the present study, we employed high-throughput screens to identify compound 3,6-dichlorobenzo[b]thiophene-2- carboxylic acid (BT2) as a novel BDK inhibitor (IC50 = 3.19 μM). BT2 binds to the same site in BDK as other known allosteric BDK inhibitors, including (S)-α-cholorophenylproprionate ((S)-CPP). BT2 binding to BDK triggers helix movements in the N-terminal domain, resulting in the dissociation of BDK from the BCKDC accompanied by accelerated degradation of the released kinase in vivo. BT2 shows excellent pharmacokinetics (terminal T1/2 = 730 min) and metabolic stability (no degradation in 240 min), which are significantly better than those of (S)-CPP. BT2, its analog 3-chloro-6- fluorobenzo[b]thiophene-2-carboxylic acid (BT2F), and a prodrug of BT2 (i.e. N-(4-acetamido-1,2,5-oxadiazol-3-yl)-3,6-dichlorobenzo[b]thiophene-2- carboxamide (BT3)) significantly increase residualBCKDCactivity in cultured cells and primary hepatocytes from patients and a mouse model of maple syrup urine disease. Administration of BT2 at 20 mg/kg/day to wild-type mice for 1 week leads to nearly complete dephosphorylation and maximal activation of BCKDC in heart, muscle, kidneys, and liver with reduction in plasmaBCAAconcentrations. The availability of benzothiophene carboxylate derivatives as stable BDK inhibitors may prove useful for the treatment of metabolic disease caused by elevated BCAA concentrations.

AB - The mitochondrial branched-chain α-ketoacid dehydrogenase complex (BCKDC) is negatively regulated by reversible phosphorylation.BCKDCkinase (BDK) inhibitors that augment BCKDC flux have been shown to reduce branched-chain amino acid (BCAA) concentrations in vivo. In the present study, we employed high-throughput screens to identify compound 3,6-dichlorobenzo[b]thiophene-2- carboxylic acid (BT2) as a novel BDK inhibitor (IC50 = 3.19 μM). BT2 binds to the same site in BDK as other known allosteric BDK inhibitors, including (S)-α-cholorophenylproprionate ((S)-CPP). BT2 binding to BDK triggers helix movements in the N-terminal domain, resulting in the dissociation of BDK from the BCKDC accompanied by accelerated degradation of the released kinase in vivo. BT2 shows excellent pharmacokinetics (terminal T1/2 = 730 min) and metabolic stability (no degradation in 240 min), which are significantly better than those of (S)-CPP. BT2, its analog 3-chloro-6- fluorobenzo[b]thiophene-2-carboxylic acid (BT2F), and a prodrug of BT2 (i.e. N-(4-acetamido-1,2,5-oxadiazol-3-yl)-3,6-dichlorobenzo[b]thiophene-2- carboxamide (BT3)) significantly increase residualBCKDCactivity in cultured cells and primary hepatocytes from patients and a mouse model of maple syrup urine disease. Administration of BT2 at 20 mg/kg/day to wild-type mice for 1 week leads to nearly complete dephosphorylation and maximal activation of BCKDC in heart, muscle, kidneys, and liver with reduction in plasmaBCAAconcentrations. The availability of benzothiophene carboxylate derivatives as stable BDK inhibitors may prove useful for the treatment of metabolic disease caused by elevated BCAA concentrations.

UR - http://www.scopus.com/inward/record.url?scp=84905378216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905378216&partnerID=8YFLogxK

U2 - 10.1074/jbc.M114.569251

DO - 10.1074/jbc.M114.569251

M3 - Article

C2 - 24895126

AN - SCOPUS:84905378216

VL - 289

SP - 20583

EP - 20593

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 30

ER -